The Global Positive Expiratory Pressure (PEP) Devices market is estimated to reach over USD 1.89 billion by 2030, exhibiting a CAGR of 8.0% during the forecast period.
Positive expiratory pressure therapy (PEP) is performed for airway clearance therapy. A participant in this therapy breathes through a portable mouthpiece or mask. This allows air to pass past the mucus in the lungs and away from the airway walls. The device facilitates unrestricted air passage and requires active inhaled air expiration against resistance. The growth in COPD prevalence due to increased smoking and drinking in industrialized countries, as well as the recent introductions of innovative oscillatory PEP, are pushing the positive expiratory pressure devices market. The rising frequency of chronic pulmonary disorders and technological developments drive market expansion. The PEP devices market is growing due to an ageing population and an increase in chronic disease occurrences.
However, in low-income countries, a lack of awareness regarding technologically advanced airway clearing medicines is projected to stymie the worldwide Positive Expiratory Pressure Devices market growth. Furthermore, the market is expected to advance due to the time-consuming old airway clearance techniques.
The Positive Expiratory Pressure (PEP) Devices market is segmented on the basis of Product, Forms and Sales channels. By product, the market is segmented as Probiotics, Prebiotics, Enzymes and Other Products. The forms segment includes Capsules, Tablets, Liquid and Other Forms. On the basis of sales channel, the market is categorized into Modern Trade, Convenience Stores, Specialty Stores, Multi-brand Stores, Online Retailing and Other Sales Channels.
Based on product type, the high-pressure PEP (26-102cm H2O) segment is accounted as a significant contributor to the Positive Expiratory Pressure (PEP) Devices market.
The global PEP devices market can be divided into two product types: high-pressure PEP (26-102cm H2O) and low-pressure PEP (5-20cm H2O). The high-pressure PEP category earned the most revenue, owing to increased patient compliance with high-pressure devices and increased bronchodilation achieved by pressures more significant than 26 cm H2O. The enhanced patient initiatives to shorten hospital stays are expected to grow the high-pressure PEP segment. PEP devices with high pressure are used to give high levels of positive expiratory pressure (PEP) to the lungs. These devices are commonly utilized in individuals suffering from the chronic obstructive pulmonary disease (COPD), asthma, or other respiratory disorders requiring improved airway clearance. High-pressure PEP devices can be mechanical or electrical, and they can generate the appropriate level of PEP through various processes. Some high-pressure PEPs can be modified to meet the needs of the patient's breathing by turning a knob on the device known as an expiratory resistance control valve, or ERV.
The COPD segment witnessed growth at a rapid rate.
The market will be led by chronic obstructive pulmonary disease (COPD). COPD is caused by an obstruction in the airways, causing difficulty breathing, and is primarily caused by tobacco smoking. According to a 2019 WHO (World Health Organization) report, the chronic obstructive pulmonary disease is the third leading cause of death worldwide. Growing patient awareness for the creation of a shared platform for COPD sufferers is likely to boost the segment's growth during the forecast period.
In the region, the North America Positive Expiratory Pressure (PEP) Devices market holds a significant revenue share.
North America dominates the positive expiratory pressure (PEP) market because of the increasing patient awareness in the region. Some of the factors driving the oscillatory positive expiratory pressure (OPEP) market during the forecast period include the rising prevalence of chronic obstructive pulmonary disease (COPD), increasing technological advancements, rising prevalence of asthma, and continuous technological and research development. The increasing frequency of chronic illnesses, on the other hand, will create several opportunities, resulting in the rise of the positive expiratory pressure (PEP) market within the time period stated. Due to an expanding patient pool and raised spending on healthcare infrastructure development by developing countries, the Asia-Pacific region is projected to expand during the projected period.
The key players in the Positive Expiratory Pressure (PEP) Devices market have shifted their focus towards forming significant approaches such as mergers, investments, and joint ventures of main and domestic players to enhance product portfolios & strengthen their market footprint across the globe. Some of the major key players in the Positive Expiratory Pressure (PEP) Devices market are Smiths Medical, Inc. (ICU Medical), Philips Respironics, Monaghan Medical Corporation, R. Cegla GmbH & Co. KG, PARI GmbH, AirPhysio, Medica Holdings, LLC, DR Burton Healthcare and SoloPep.